Lorentzon, M.
Nilsson, A. G.
Johansson, H.
Kanis, J. A.
Mellström, D.
Sundh, D. http://orcid.org/0000-0002-4301-6796
Funding for this research was provided by:
Vetenskapsr?det
IngaBritt och Arne Lundbergs Forskningsstiftelse
Sahlgrenska Universitetssjukhuset
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Article History
Received: 24 October 2018
Accepted: 21 January 2019
First Online: 25 February 2019
Compliance with ethical standards
:
: Professor Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, UCB Pharma, and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health. Dr. Nilsson has received lecture fees from Shire and Pfizer. Professor Kanis reports grants from Amgen, Eli Lilly, and Radius Health; non-financial support from Medimaps, and Asahi; and other support from AgNovos. Professor Kanis is the architect of FRAX® but has no financial interest. All other authors state that they have no conflicts of interest.